ライフサイエンスコーパス: antifungal agent

1 C2'deOAmB is an exceptionally promising new antifungal agent.

2 eatment with ketoconazole, a clinically used antifungal agent.

3 bilities of Candida spp. to this widely used antifungal agent.

4 ntibiotics, is a Streptomyces-derived potent antifungal agent.

5 ndida, which was easily treated with an oral antifungal agent.

6 s agent remains a viable systemically active antifungal agent.

7 riconazole should be considered a first-line antifungal agent.

8 munomodulatory activity and toxicity of this antifungal agent.

9 e (BCYE alpha medium) and with natamycin, an antifungal agent.

10 ndicate the great potential of 28 as a novel antifungal agent.

11 t of fungal cell walls, chitosan is a potent antifungal agent.

12 sceptibility to azoles, the most widely used antifungal agent.

13 is antibacterial aminoglycoside into a novel antifungal agent.

14 , showing the effectiveness of the REO as an antifungal agent.

15 nal release of a cationic beta-peptide-based antifungal agent.

16 ceptibility profiles to clinically available antifungal agents.

17 of birth defects previously linked to azole antifungal agents.

18 opathies, and broad spectrum antibiotics and antifungal agents.

19 e that belongs to the syringomycin family of antifungal agents.

20 s as inhibitors of the OAT1 and OAT3, and as antifungal agents.

21 the pharmacology and pediatric use of newer antifungal agents.

22 ced susceptibility to these well-established antifungal agents.

23 diagnostic tools and the pharmacokinetics of antifungal agents.

24 ibilities of Candida spp. to these important antifungal agents.

25 ing pheromones, tunicamycin, and azole-class antifungal agents.

26 from seeded blood cultures in the absence of antifungal agents.

27 suspensions of Candida spp., with or without antifungal agents.

28 th and without the addition of commonly used antifungal agents.

29 for a spectrum of both novel and established antifungal agents.

30 me species vary in their susceptibilities to antifungal agents.

31 , and the safety and efficacy of appropriate antifungal agents.

32 pulations, including increased resistance to antifungal agents.

33 ast species with decreased susceptibility to antifungal agents.

34 potent activity of selected, newer triazole antifungal agents.

35 tibacterial agents, it is also an issue with antifungal agents.

36 ells are relatively resistant to many common antifungal agents.

37 ida with reduced susceptibility to the azole antifungal agents.

38 orted to exhibit decreased susceptibility to antifungal agents.

39 ificance of in vitro resistance to the newer antifungal agents.

40 a new enzymatic target for antibacterial or antifungal agents.

41 95 to 99% agreement) for all the species and antifungal agents.

42 cterial agents, and it is also an issue with antifungal agents.

43 acrolide antibiotics are naturally occurring antifungal agents.

44 chinocandins were higher than those of other antifungal agents.

45 serve as a lead structure for a new class of antifungal agents.

46 icans, inhibitors of Ess1 might be useful as antifungal agents.

47 and remains highly susceptible to available antifungal agents.

48 minimum fungicidal concentrations (MFCs) of antifungal agents.

49 OPC, possibly reducing the usage of systemic antifungal agents.

50 neoformans and represents a novel target for antifungal agents.

51 iated with long-term treatment with existing antifungal agents.

52 ghly susceptible to both new and established antifungal agents.

53 pressive rapamycin analogs have potential as antifungal agents.

54 esulted in an increased demand for new azole antifungal agents.

55 ticular significance due to the need for new antifungal agents.

56 eptibilities of Candida spp. to a variety of antifungal agents.

57 munity, underscoring the urgent need for new antifungal agents.

58 as created a need for the development of new antifungal agents.

59 ains inhibited in ergosterol biosynthesis by antifungal agents.

60 turase (5-desaturase), may lead to effective antifungal agents.

61 is a potential target for antibacterial and antifungal agents.

62 med biofilms, which are resistant to current antifungal agents.

63 s, herbicides, antiviral, antibacterial, and antifungal agents.

64 photericin B (AmB) is one of the most potent antifungal agents.

65 to remove and intrinsically tolerant to most antifungal agents.

66 heir increasing prevalence and resistance to antifungal agents.

67 between PD-1 inhibitors and immunomodulatory antifungal agents.

68 of kanamycin A, show very strong activity as antifungal agents.

69 deal candidates for the development of novel antifungal agents.

70 s of several synthetic and naturally derived antifungal agents.

71 FDA-approved member of the triazole class of antifungal agents.

72 n that should inspire the development of new antifungal agents.

73 the potential to decrease the use of empiric antifungal agents.

74 should focus on long-term administration of antifungal agents.

75 nsuming, delaying treatment with appropriate antifungal agents.

76 rusei were classified as susceptible to both antifungal agents.

77 ocular tissues despite prolonged exposure to antifungal agents.

78 e by systemic administration of conventional antifungal agents.

79 lems associated with the use of conventional antifungal agents.

80 ective advantage in the presence of specific antifungal agents.

81 i were classified as susceptible (S) to both antifungal agents.

82 nd resistance rates of newer and established antifungal agents.

83 inical features may guide the use of initial antifungal agents.

84 al communities displaying resistance to most antifungal agents.

85 vs 18%, p=0.03) and concomitant therapy with antifungal agents (75% vs 9%, p=0.006).

86 f a key intermediate in the synthesis of the antifungal agent alternaric acid is also described.

87 Amphotericin is the most commonly used antifungal agent, although fluconazole is being used mor

88 The membrane-active antifungal agent amphotericin B (AmB) is one of the few

89 argeting antibiotic gramicidin and the known antifungal agent amphotericin B and were not toxic at th

90 The susceptibility of the isolates to the antifungal agents amphotericin B, flucytosine, fluconazo

91 . tropicalis, and 7 C. krusei) against seven antifungal agents (amphotericin B, fluconazole, voricona

92 riconazole as well as four licensed systemic antifungal agents (amphotericin B, flucytosine, fluconaz

93 and 48-h BMD MICs was observed for all three antifungal agents: amphotericin B, 99.1% and 97%, respec

94 acology and clinical indications of existing antifungal agents and also the development of new broad-

95 e others had a good response to a variety of antifungal agents and antiretroviral therapy.

96 ff values (ECVs) for the systemically active antifungal agents and both common and uncommon species o

97 e new 2,3-dideoxyglucosides can be useful as antifungal agents and condiments in foods.

98 the mechanisms of action of these classes of antifungal agents and demonstrate the potential utility

99 Advances in antifungal agents and diagnostic methods offer the poten

100 New antifungal agents and diagnostic tests may improve the o

101 alivary histatins (Hsts) are potent in vitro antifungal agents and have great promise as therapeutic

102 findings raise questions about the effect of antifungal agents and health care exposures (e.g., yogur

103 The limitations of the current antifungal agents and opportunities for new developments

104 sterols in eukaryotes, the major targets for antifungal agents and prospective targets for treatment

105 for the development of urgently needed novel antifungal agents and strategies.

106 ude validation of 24-h reading times for all antifungal agents and the establishment of species-speci

107 ndard for investigating both the activity of antifungal agents and the pathogenesis of this disease.

108 this clinically vital but also highly toxic antifungal agent, and (iii) suggest that the capacity fo

109 sible small molecules: pyrrolnitrin, a known antifungal agent, and a chromene that potently enhances

110 otericin B was selected as a membrane-active antifungal agent, and caspofungin was selected as a cell

111 e isolated before the widespread use of this antifungal agent, and only three were in fact drug resis

112 tic route a promising target for herbicides, antifungal agents, and antibiotics.

113 sive strategies, dosing, durations of use of antifungal agents, and definitions of invasive infection

114 stic methods, the pharmacology and dosing of antifungal agents, and the absence of interventional pha

115 target for drug discovery of next-generation antifungal agents, and we found two aromatic acylhydrazo

116 l agents (quinolones, antiviral therapy, and antifungal agents), antiemetic agents, and analgesic age

117 an important public health concern, and new antifungal agents are highly desirable.

118 Efficient and pathogen-specific antifungal agents are required to mitigate drug resistan

119 h superior in some cases compared with older antifungal agents, are still far from satisfactory.

120 for rational design of new, more efficacious antifungal agents as well as insight into the molecular

121 mportant implications for the development of antifungal agents, as well as the understanding of polym

122 Clinical Question: Are antifungal agents associated with lower rates of mortali

123 Caspofungin is a safe antifungal agent at vitreal concentrations of 0.41 to 4.

124 sk factors (including candidiasis and use of antifungal agents at the current examination, a low CD4:

125 In bottles containing antifungal agents, Bactec FX recovered 83.1% of isolates

126 In the absence of antifungal agents, Bactec FX recovered 97.4% of Candida

127 ons (MFCs), with higher MFCs of the triazole antifungal agents being seen for the South African linea

128 Our data suggest that the natural antifungal agent beta-glucanase may support morphologic

129 Drugs targeting calcineurin are potent antifungal agents but also perturb human immunity thereb

130 ed the susceptibility of planktonic cells to antifungal agents, but an antagonistic effect was observ

131 the susceptibilities of filamentous fungi to antifungal agents by the Clinical and Laboratory Standar

132 s were tested 20 times each against the five antifungal agents by using a common lot of RPMI agar.

133 Antifungal agents can effectively treat mucosal candidia

134 viously reported that itraconazole, a common antifungal agent, can clinically improve or cure infanti

135 -step synthesis of the highly functionalized antifungal agent CANCIDAS (caspofungin acetate, 2) is de

136 id antifungal susceptibility testing for the antifungal agent caspofungin can be performed using flow

137 d in the treatment of alcohol abuse) and the antifungal agent chlordantoin.

138 also identified the approved small-molecule antifungal agent ciclopirox as a novel pan-histone demet

139 visiae conferred increased resistance to the antifungal agent cilofungin (LY121019), an echinocandin

140 The combination of antifungal agents (cinnamon bark oil, zinc gluconate and

141 log2 dilution range for the respective yeast-antifungal agent combinations.

142 that are typically resistant to traditional antifungal agents, could potentially have a role in devi

143 of birth defects previously linked to azole antifungal agents: craniosynostosis, other craniofacial

144 The biofilms are resistant to a range of antifungal agents currently in clinical use, including a

145 m temperature incubation and the addition of antifungal agents decreased growth of Candida species in

146 bitors used in the study were nitroimidazole antifungal agents, diltiazem, verapamil, and troleandomy

147 n bonding and decrease the susceptibility of antifungal agents during chemotherapy.

148 ecipients vary, particularly with regards to antifungal agent employed, and duration of therapy.

149 e promising leads for the development of new antifungal agents, especially against C. neoformans.

150 in the clinical laboratory for the four new antifungal agents evaluated.

151 This is a rational approach because existing antifungal agents fail to eradicate the infection in the

152 CYP51), complexed with posaconazole, another antifungal agent fluconazole and an experimental inhibit

153 s of Candida glabrata resistant to the azole antifungal agent fluconazole was evaluated on a collecti

154 Inhibitors of CYP51 include triazole antifungal agents fluconazole and itraconazole, drugs us

155 f these agents with those of the established antifungal agents fluconazole, itraconazole, amphoterici

156 dubliniensis are susceptible to established antifungal agents, fluconazole-resistant strains have be

157 kn7, governs sensitivity to Na+ ions and the antifungal agent fludioxonil, negatively controls melani

158 nd 1, warrant further investigation as novel antifungal agents for drug-resistant Candida infections.

159 The MICs of various antifungal agents for germinated conidia were almost ide

160 For the prototype panel, we chose eight antifungal agents for in vitro testing (amphotericin B,

161 earlier diagnosis and selection of effective antifungal agents for patients with IA.

162 The role of newer antifungal agents for this population, such as the new a

163 Flucytosine and itraconazole are the only antifungal agents for which the Clinical Laboratory and

164 A limited number of antifungal agents from only a few drug classes are avail

165 A new class of antifungal agents has been discovered which exert their

166 Overuse of antifungal agents has resulted in the selection of natur

167 Clinical needs for novel antifungal agents have altered steadily with the rise an

168 Calcineurin inhibitors (CNI) and azole antifungal agents have been reported to interact in a di

169 Meanwhile, six new antifungal agents have just reached, or are approaching,

170 in reports of fungal resistance to multiple antifungal agents have made fungal infections a major th

171 The newer systemic antifungal agents have no significant advantage over gri

172 agnostic systems and the introduction of new antifungal agents have significantly improved outcomes i

173 s is intimately dependent on the efficacy of antifungal agents; however, fungi that are resistant to

174 ndins, but no change in sensitivity to other antifungal agents; (ii) in vitro glucan synthase activit

175 ility that MtDef5 might be useful as a novel antifungal agent in transgenic crops.

176 e, a detailed understanding of the available antifungal agents in children is crucial for the success

177 s and mechanisms of action of all classes of antifungal agents in clinical use or with clinical poten

178 concentrations of semisynthetic pneumocandin antifungal agents in human plasma.

179 of chitin synthase, effective as therapeutic antifungal agents in humans and easily degradable insect

180 cleoside antibiotics that act as therapeutic antifungal agents in humans and easily degraded insectic

181 ingly reminiscent of the reduced efficacy of antifungal agents in immunocompromised animals.

182 se of prophylactic systemic antibacterial or antifungal agents in patients with necrotizing pancreati

183 permitting earlier selection of appropriate antifungal agents in the clinical setting.

184 The combination of antifungal agents in the emulsions has demonstrated to b

185 ach isolate was tested 20 times with the two antifungal agents in the five laboratories by using a lo

186 aphic analysis of the oxidase and the use of antifungal agents in the prophylaxis of chronic granulom

187 nefit to adding oral voriconazole to topical antifungal agents in the treatment of severe filamentous

188 il nanoemulsions can act as highly efficient antifungal agents in vitro.

189 This review summarizes information on new antifungal agents, including current data on their clini

190 features, and also reviews the use of newer antifungal agents, including lipid-associated amphoteric

191 of fungal pathogens, the development of new antifungal agents, including vaccines, becomes a global

192 Newer antifungal agents, including voriconazole and caspofungi

193 test whether posaconazole, a broad-spectrum antifungal agent inhibiting ergosterol biosynthesis, exh

194 Bifonazole, a broad spectrum antifungal agent, inhibits monooxygenase activity and in

195 The echinocandin class of antifungal agents is considered to be the first-line tre

196 Routine use of antifungal agents is not recommended.

197 The Food and Drug Administration-approved antifungal agent, itraconazole (ITZ), has been increasin

198 A red flag has been raised with the triazole antifungal agents, itraconazole and voriconazole, causin

199 (ISAV) is a novel, broad-spectrum, triazole antifungal agent (IV and by mouth [PO]) developed for th

200 and is also inhibited by the presence of the antifungal agent ketoconazole.

201 unomodulatory properties, the newer class of antifungal agents, known as echinocandins, has the poten

202 e stereochemical determination of the potent antifungal agents leupyrrin A1 and B1 and the total synt

203 Its resistance to certain antifungal agents makes it difficult to treat, especiall

204 tencies of the new triazole and echinocandin antifungal agents may provide effective therapeutic opti

205 st that itraconazole, an orally administered antifungal agent, may be an effective adjunctive therapy

206 susceptibilities of Candida spp. to the new antifungal agent MK-0991, a glucan synthase inhibitor.

207 representative of the echinocandin class of antifungal agents, MK-0991.

208 ence of resistance to our limited arsenal of antifungal agents, necessitating the development of nove

209 Strategies for the appropriate use of antifungal agents need to be developed to prevent furthe

210 ns strains are particularly resistant to the antifungal agents now in use.

211 The pneumocandins are potent antifungal agents of the echinocandin class which are un

212 elective synthesis of the acyclic portion of antifungal agent plakinic acid A, containing two remotel

213 rise of fungi that are resistant to existing antifungal agents poses a substantial threat to human he

214 lity testing of filamentous fungi (molds) to antifungal agents, quality control (QC) disk diffusion z

215 The overall agreement for each antifungal agent ranged from 96% for ravuconazole to 100

216 Voriconazole was 1 of 2 antifungal agents recommended for treatment of fungal in

217 ylaxis, consensus on the strategy, choice of antifungal agent(s), route of administration, and durati

218 spp., enable clinicians to more quickly make antifungal agent selections, and potentially decrease pa

219 as defined as the concentration at which the antifungal agent significantly inhibits the organism.

220 These compounds include anticancer and antifungal agents, statins, alverine citrate, and dyclon

221 Moreover, HHK3 is a molecular target for antifungal agents such as fludioxonil, which thereby int

222 it 3-4 times more potent than commonly used antifungal agents such as ketoconazole (1.5 muM) or itra

223 ocandins but are not yet available for older antifungal agents, such as amphotericin B, flucytosine,

224 Novel antifungal agents, such as the echinocandins and the sec

225 Prophylactic use of antifungal agents, such as the echinocandins, during per

226 caffeine resistance show cross-resistance to antifungal agents, suggesting that related heterochromat

227 dk7 and raises the possibility of developing antifungal agents targeting CAKs.

228 ineurin and provides a foundation to develop antifungal agents targeting calcineurin to deploy agains

229 pecificity and enable the rational design of antifungal agents targeting Sgl1.

230 nvestigated the MIC reproducibility of seven antifungal agents tested against 25 dermatophyte isolate

231 k and reference panels were observed for all antifungal agents tested against the 99 clinical isolate

232 The antifungal agents tested included amphotericin B, flucyt

233 Antifungal agents tested included ciclopirox, fluconazol

234 Of the antifungal agents tested, ravuconazole and voriconazole

235 Sertaconazole nitrate is an antifungal agent that exhibits anti-inflammatory activit

236 Voriconazole is a new triazole antifungal agent that has potent activity against many i

237 Micafungin is an echinocandin antifungal agent that has recently been approved for the

238 Caspofungin is a synthetic echinocandin antifungal agent that inhibits the synthesis of beta(1,3

239 Nystatin (nys) is an antifungal agent that preferentially forms ion channels

240 gs demonstrate that EntV has potential as an antifungal agent that targets virulence rather than viab

241 We determined whether cercosporamide, an antifungal agent that was recently shown to act as a uni

242 Despite the availability of powerful antifungal agents that are active against Cryptococcus n

243 a-Peptides comprise a promising new class of antifungal agents that could help address problems assoc

244 s been realized with the introduction of new antifungal agents that have proved to be safer than thos

245 Echinocandins are a group of antifungal agents that target 1,3-beta-glucan synthase,

246 While the development of new antifungal agents that target the essential enzyme, dihy

247 In the presence of antifungal agents, the Bactec FX recovery time was signi

248 sence of therapeutic levels of commonly used antifungal agents, the Bactec FX system demonstrated a s

249 o effect on the toxicity of a novel class of antifungal agents, the dicationic aromatic compounds (DA

250 Among the systemically active antifungal agents, the echinocandins appear to be the mo

251 road-spectrum triazoles and a newer class of antifungal agents, the echinocandins.

252 For BC bottles without the addition of antifungal agents, the median LTD for VersaTREK was 2.2

253 Despite treatment with antifungal agents, the mortality rate attributed to thes

254 AMS guidelines likely apply to stewarding of antifungal agents, there are additional considerations u

255 Due to their effectiveness as antifungal agents, three semisynthetic derivatives have

256 d interest in studying novel combinations of antifungal agents to determine whether superior outcomes

257 ntrations (MECs) (CLSI M38-A method) of five antifungal agents to identify optimal testing guidelines

258 There is significant clinical need for new antifungal agents to manage infections with pathogenic s

259 ME1111 is a novel small molecule antifungal agent under development for the topical treat

260 he era of modern immunosuppressive and newer antifungal agent use have not been defined.

261 Ciclopirox olamine (CPX), an off-patent antifungal agent used to treat mycoses of skin and nails

262 ism and fluconazole remained the predominant antifungal agent used.

263 s of the four currently available classes of antifungal agents used in the management of systemic fun

264 We conclude that in vitro resistance to antifungal agents used in the treatment of cryptococcosi

265 linical efficacy and toxicity of the various antifungal agents used to prevent infection, and offers

266 d to be less hemolytic than the FDA-approved antifungal agent voriconazole (VOR).

267 cycles exemplified by the methylation of the antifungal agent voriconazole.

268 All 35 patients were treated with antifungal agents (voriconazole, with or without liposom

269 tration of glucose decreased the activity of antifungal agents; voriconazole was the most affected dr

270 17 responses remained defective even when an antifungal agent was administered throughout DSS exposur

271 ical agreement (CA) between methods for each antifungal agent was assessed using previously determine

272 s, and pre-ICU exposure to antibacterial and antifungal agents was associated with greater ICU-onset

273 A review of common topical antifungal agents was done.

274 rium lactis resistant to currently available antifungal agents, was cured of her infection with fosma

275 In the course of screening for antifungal agents we have discovered a novel compound is

276 With the limited choices of topical antifungal agents, we were faced with Cladosporium kerat

277 Membrane permeability changes caused by the antifungal agent were measured by flow cytometry using p

278 The MICs for seven antifungal agents were determined in a central laborator

279 Effects of glucose on the susceptibility of antifungal agents were investigated against Candida spp.

280 Antifungal agents were not associated with obesity (OR =

281 The in vitro assays of free antifungal agents were performed against five fungal str

282 ve QC limits for the two QC strains and five antifungal agents when tested by the Etest methodology a

283 Breakpoints are used to predict whether an antifungal agent will be clinically effective against a

284 s to characterize the mechanism of action of antifungal agents will be of great use in the antifungal

285 d suggest that development of CYP51-specific antifungal agents will continue to be a challenge.

286 The future development of new antifungal agents will rest with those who employ synthe

287 ich no resistance could be identified and an antifungal agent with activity against diverse fungal pa

288 Caspofungin acetate, a new antifungal agent with minimal toxicity, may provide a be

289 Anidulafungin is an echinocandin antifungal agent with potent activity against Candida sp

290 e efficacy of anidulafungin, an echinocandin antifungal agent with potent anti-Candida activity, in t

291 f any positive test can obviate the need for antifungal agents with a negative predictive value of 10

292 e AG backbone, interesting antibacterial and antifungal agents with a novel mechanism of action have

293 Biophysical interactions between antifungal agents with glucose molecules were investigat

294 Supplementation of antifungal agents with interferon-gamma treatment slowed

295 There is an important medical need for new antifungal agents with novel mechanisms of action to tre

296 ens highlighting the need for more effective antifungal agents with novel modes of action.

297 their metabolic activity in the presence of antifungal agents with that in their absence.

298 da spp. and C. neoformans against a range of antifungal agents with the exceptions only of miconazole

299 infections is now possible with a variety of antifungal agents, with different spectrums of activity,

300 sceptible to the currently licensed systemic antifungal agents, with the exception of voriconazole.